To understand why, lets look at the concept of the medications half-life and how it applies to semaglutide
This option is HSA and FSA eligible, further reducing out-of-pocket costs for those with qualified health savings accounts
More importantly, the hazard ratio for major adverse cardiovascular events (including cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina) for the pooled tirzepatide groups versus glargine was 0.74 (95% CI 0.511.08), suggesting no increased cardiovascular risk with tirzepatide compared to insulin glargine
A study by the Institute of Clinical and Economic Review showed that in order for these medications to be priced effectively such that the risk of cardiovascular disease was higher than the cost of these weight loss drugs, they would need to be priced annually somewhere between $7,500 and $9,800 per patient per year
Available from: Gorgojo-Martinez JJ, Mezquita-Raya P, Carretero-Gomez J, et al
Semaglutide GLP-1 helps to facilitate consistent, stable, and healthy weight loss over a period of time
%20(1).png)
